Joseph Landolfi

4.7k total citations
25 papers, 360 citations indexed

About

Joseph Landolfi is a scholar working on Genetics, Genetics and Molecular Biology. According to data from OpenAlex, Joseph Landolfi has authored 25 papers receiving a total of 360 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 9 papers in Genetics and 8 papers in Molecular Biology. Recurrent topics in Joseph Landolfi's work include Glioma Diagnosis and Treatment (12 papers), Cancer Research and Treatments (8 papers) and Virus-based gene therapy research (7 papers). Joseph Landolfi is often cited by papers focused on Glioma Diagnosis and Treatment (12 papers), Cancer Research and Treatments (8 papers) and Virus-based gene therapy research (7 papers). Joseph Landolfi collaborates with scholars based in United States and Israel. Joseph Landolfi's co-authors include Howard T. Thaler, Lisa M. DeAngelis, Mangala A. Nadkarni, Rik Vandenberghe, Jeffrey Rossi, Myrna R. Rosenfeld, Edward J. Dropcho, A. Garcı́a-Merino, Tatsuya Yamamoto and Josep Dalmau and has published in prestigious journals such as Journal of Clinical Oncology, Neurology and The American Journal of Surgical Pathology.

In The Last Decade

Joseph Landolfi

23 papers receiving 352 citations

Peers

Countries citing papers authored by Joseph Landolfi

Since Specialization

Citations

This map shows the geographic impact of Joseph Landolfi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joseph Landolfi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joseph Landolfi more than expected).

Fields of papers citing papers by Joseph Landolfi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joseph Landolfi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joseph Landolfi. The network helps show where Joseph Landolfi may publish in the future.

Co-authorship network of co-authors of Joseph Landolfi

This figure shows the co-authorship network connecting the top 25 collaborators of Joseph Landolfi. A scholar is included among the top collaborators of Joseph Landolfi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joseph Landolfi. Joseph Landolfi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	CTIM-20. FINAL RESULTS OF CONTROLLED IL-12 MONOTHERAPY AND IN COMBINATION WITH PD-1 INHIBITOR IN ADULT SUBJECTS WITH RECURRENT GLIOBLASTOMA 2021 ·Neuro-Oncology ·Rimas V. Lukas, (unknown), Robert Cavaliere, Joseph Landolfi, John S. Yu, Clark Chen, (unknown), Christina Amidei, Jill Buck, Nira Hadar, (unknown), (unknown), John W. Loewy, (unknown), (unknown), Laurence J.N. Cooper, E. Antonio Chiocca	3
2	Survival of subjects with recurrent glioblastoma receiving intratumoral administration of controlled IL-12 with limited exposure to dexamethasone. 2020 ·Journal of Clinical Oncology ·Rimas V. Lukas, Sylvia C. Kurz, John S. Yu, Joseph Landolfi, Ganesh Rao, Christina Amidei, Jill Buck, Nira Hadar, (unknown), (unknown), John W. Loewy, Yunxia Wang, Nathan Demars, Arnold B. Gelb, Laurence J.N. Cooper	1
3	Immunological targeting of CD133 in recurrent glioblastoma: A multi-center phase I translational and clinical study of autologous CD133 dendritic cell immunotherapy. 2017 ·Journal of Clinical Oncology ·Jeremy Rudnick, Karen Fink, Joseph Landolfi, James M. Markert, David Piccioni, Michael Glantz, Steven J. Swanson, (unknown), John S. Yu	17
4	OS09.6 Long-term follow-up data from 126 patients with recurrent high grade glioma from three Phase 1 trials of Toca 511 and Toca FC: Update and justification for a Phase 2/3 trial 2017 ·Neuro-Oncology ·Manish K. Aghi, Michael A. Vogelbaum, Steven N. Kalkanis, Daniela A. Bota, David Piccioni, B L Elder, (unknown), George J. Kaptain, Joseph Landolfi, Timothy F. Cloughesy	3
5	Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC. 2017 ·Journal of Clinical Oncology ·Timothy F. Cloughesy, Derek Ostertag, Joseph Landolfi, Tobias Walbert, Michael A. Vogelbaum, J. Bradley Elder, (unknown), Bob S. Carter, Clark Chen, Steven N. Kalkanis, Santosh Kesari, Albert Lai, Ian Lee, Linda M. Liau, Tom Mikkelsen, Phioanh L. Nghiemphu, David Piccioni, Douglas J. Jolly, Harry E. Gruber, Asha Das	1
6	PC3 - 151 Toca 5: A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined with Toca FC versus Standard of Care in Patients Undergoing Planned Resection for Recurrent Glioblastoma (GBM) or Anaplastic Astrocytoma (AA) (NCT02414165) 2016 ·Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ·Gelareh Zadeh, Daniela A. Bota, David Cachia, Joseph Landolfi, (unknown), Michael A. Vogelbaum, Tobias Walbert, (unknown), Alice Chu, Arabinda K. Das, Douglas J. Jolly, Carlos E. Ibañez, Derek Ostertag, (unknown), Timothy F. Cloughesy	2
7	ATIM-17. INVESTIGATION OF ANTI-TUMOR CELLULAR IMMUNE RESPONSE ELICITED BY TOCA 511 & TOCA FC THERAPY IN A RECURRENT HGG PHASE 1 TRIAL 2016 ·Neuro-Oncology ·Derek Ostertag, Timothy F. Cloughesy, Steven N. Kalkanis, Tom Mikkelsen, Joseph Landolfi, Bob S. Carter, Clark Chen, Asha Das, Douglas J. Jolly, Harry E. Gruber, (unknown)	1
8	DDEL-06PRELIMINARY SAFETY OF TOCA 511, A RETROVIRAL REPLICATING VECTOR, IN PATIENTS WITH RECURRENT HIGH GRADE GLIOMA ACROSS THREE SEPARATE PHASE 1 STUDIES 2015 ·Neuro-Oncology ·Steven N. Kalkanis, Manish K. Aghi, (unknown), George Kaptain, Jana Portnow, Michael A. Vogelbaum, Santosh Kesari, Tom Mikkelsen, J. Bradley Elder, Clark C. Chen, David Piccioni, David S. Baskin, (unknown), Daniela A. Bota, E. Antonio Chiocca, Greg Foltz, Derek Ostertag, Dawn Gammon, Andreas G. Niethammer, Joseph Landolfi	3
9	SURG-09RESULTS OF A DOSE ESCALATION TRIAL OF TOCA 511 WITH TOCA FC IN RECURRENT HGG UNDERGOING REPEAT RESECTION 2015 ·Neuro-Oncology ·Michael A. Vogelbaum, Santosh Kesari, Steven N. Kalkanis, Tom Mikkelsen, Joseph Landolfi, J. Bradley Elder, Clark C. Chen, Joan M. Robbins, Derek Ostertag, Doug J. Jolly, (unknown), Jamey Skillings, (unknown), Timothy F. Cloughesy	1
10	IMCT-20ASSOCIATION OF SURVIVAL AND PROGRESSION-FREE SURVIVAL WITH IMMUNE RESPONSE IN HLA-A2+ NEWLY-DIAGNOSED GBM PATIENTS IN RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 TRIAL OF DENDRITIC CELL (DC) IMMUNOTHERAPY WITH ICT-107 2015 ·Neuro-Oncology ·Patrick Y. Wen, David A. Reardon, Surasak Phuphanich, Robert Aiken, Joseph Landolfi, (unknown), Jay‐Jiguang Zhu, Michael Glantz, David M. Peereboom, James M. Markert, Renato V. LaRocca, Donald M. O’Rourke, Karen Fink, Lyndon Kim, Michael L. Gruber, Glenn J. Lesser, (unknown), Radleigh G. Santos, Clemencia Pinilla, John S. Yu	2
11	Ascending dose trials of a retroviral replicating vector (Toca 511) in patients with recurrent high-grade glioma. 2014 ·Journal of Clinical Oncology ·Joan M. Robbins, Tiffany Huang, Douglas J. Jolly, Noriyuki Kasahara, Manish K. Aghi, Michael A. Vogelbaum, Timothy F. Cloughesy, Susan M. Chang, Santosh Kesari, Tom Mikkelsen, Steven N. Kalkanis, Joseph Landolfi, J. Bradley Elder, E. Antonio Chiocca, Harry E. Gruber, (unknown)	1
12	AT-60 * A RANDOMIZED DOUBLE BLIND PLACEBO-CONTROLLED PHASE 2 TRIAL OF DENDRITIC CELL (DC) VACCINE ICT-107 FOLLOWING STANDARD TREATMENT IN NEWLY DIAGNOSED PATIENTS WITH GBM 2014 ·Neuro-Oncology ·(unknown), David A. Reardon, Surasak Phuphanich, Robert Aiken, Joseph Landolfi, William T. Curry, (unknown), Michael Glantz, (unknown), James M. Markert, R. V. Larocca, Donald M. O’Rourke, Karen Fink, (unknown), Michael L. Gruber, Glenn J. Lesser, Edward Pan, (unknown), John S. Yu	19
13	A randomized, double‑blind, controlled phase IIb study of the safety and efficacy of ICT‑107 in newly diagnosed patients with glioblastoma multiforme following resection and chemoradiation. 2012 ·Journal of Clinical Oncology ·Elma S. Hawkins, Robert Aiken, James R. Chandler, Karen Fink, Michael Glantz, Jai Grewal, Michael L. Gruber, Santosh Kesari, Joseph Landolfi, Renato V. LaRocca, Glenn J. Lesser, James M. Markert, Tina Mayer, Donald M. O’Rourke, David M. Peereboom, Surasak Phuphanich, David Schiff, Andrew E. Sloan, Baldassarre Stea, Jay‐Jiguang Zhu	2
14	Herpes Encephalitis Masquerading as Tumor 2011 ·PubMed ·(unknown), Joseph Landolfi	7
15	Rosai-Dorfman disease manifesting as intracranial and intraorbital lesion 2008 ·Journal of Neuro-Oncology ·Archana Hinduja, (unknown), (unknown), David Nochlin, Joseph Landolfi	29
16	Gliosarcoma Arising in Oligodendroglial Tumors (“Oligosarcoma”) 2007 ·The American Journal of Surgical Pathology ·Fausto J. Rodríguez, Bernd W. Scheithauer, Robert B. Jenkins, Peter C. Burger, (unknown), Euvgeni Vlodavsky, (unknown), Joseph Landolfi	40
17	Orchiectomy for suspected microscopic tumor in patients with anti-Ma2-associated encephalitis 2006 ·Neurology ·(unknown), Rik Vandenberghe, A. Garcı́a-Merino, Tatsuya Yamamoto, Joseph Landolfi, Myrna R. Rosenfeld, Jeffrey Rossi, Brian Thiessen, Edward J. Dropcho, Josep Dalmau	70
18	Paraneoplastic limbic encephalitis and possible narcolepsy in a patientwith testicular cancer: Case study 2003 ·Neuro-Oncology ·Joseph Landolfi, Mangala A. Nadkarni	33
19	Chronic Malignant Pain in Cancer Patients 1999 ·CNS Spectrums ·Joseph Landolfi	32
20	Adult brainstem gliomas 1998 ·Neurology ·Joseph Landolfi, Howard T. Thaler, Lisa M. DeAngelis	56

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact